 |
01/05/12 - |
CanBas' CBP501 Receives FDA Orphan Drug Designation
Source: CanBas Co., Ltd.
CanBas Co., Ltd. today announced that the United States Food and Drug Administration (FDA) granted Orphan drug designation for CBP501 "for use in combination with cisplatin and pemetrexed for treatment of patients with mesothelioma."
Read More...
|
| |
12/13/11 - |
Treatment of Patients with Malignant Mesothelioma utilizing Photodynamic Therapy with Pinnacle Biologics compound PHOTOFRIN
Source: Pinnacle Biologics, Inc.
Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has obtained approval for an Orphan Drug Designation (ODD) for their product PHOTOFRIN (porfimer sodium) as adjuvant therapy to surgery in the treatment of malignant pleural mesothelioma.
Read More...
|
| |
10/21/11 - |
MolMed expands Phase III trial of NGR-hTNF for the treatment of mesothelioma in the United States
Source: MolMed S.p.A.
MolMed S.p.A.announces the expansion in the United States of a pivotal Phase III trial of its investigational anticancer drug NGR-hTNF in malignant pleural mesothelioma, with treatment of the first patient at one of the most prestigious US Universities in New York.
Read More...
|
| |
06/01/11 - |
Karmanos' Dr. Harbut studies protein markers that could detect malignant mesothelioma
Source: Barbara Ann Karmanos Cancer Institute
Michael Harbut, M.D., MPH., FCCP, director of the National Center for Vermiculite and Asbestos-Related Diseases and Environmental Cancer Program at the Barbara Ann Karmanos Cancer Center, has co-authored an investigational test based on a panel of 13 protein markers in the blood that may be able to detect malignant mesothelioma in people exposed to asbestos, even when the disease is in its earliest stages.
Read More...
|
| |
05/02/11 - |
M. D. Anderson Researchers Demonstrate Power of miRview(TM) mets to Identify Tissue of Origin in Carcinoma of Unknown Primary
Source: Rosetta Genomics, Ltd.
Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results of a joint study with researchers at the University of Texas, M. D. Anderson Cancer Center show that Rosetta Genomics' miRview(TM) mets is a powerful tool to identify Tissue of Origin in Carcinoma of Unknown Primary (CUP) patients.
Read More...
|
| |
03/18/11 - |
Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Source: Polaris Group
Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free survival.
Read More...
|
HOME